This study aimed to describe rates of antipsychotic medication use and the association between their use and demographics, clinical variables, and the use of behavioral/education services among children with ASD. For children with ASD ages 2–11 (n = 4749) and those 12–17 (n = 401), 5.4 and 17.7% were prescribed at least one atypical antipsychotic medication respectively. In the multivariable model of young children, older age, use of multiple psychotropic medications, prior ASD diagnosis, non-white Hispanic race/ethnicity, and oppositional defiant problems were associated with antipsychotic use. Among older children, only older age was associated with antipsychotic use. In at least one age group, antipsychotic medication use was also related to behaviour, family and occupational therapy, public insurance, site region, externalizing problems, body mass index, and sleep and gastrointestinal problems.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Achenbach, T. M., & Rescorla, L. A. (2000). Manual for the ASEBA Preschool forms and Profiles. Burlington, VT: University of Vermont Department of Psychiatry.
Almandil, N. B., Liu, Y., Murray, M. L., Besag, F. M., Aitchison, K. J., & Wong, I. C. (2013). Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Pediatric Drugs, 15(2), 139–50.
Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., … & Wagner, A. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1143–54.
Barnard, L., Young, A. H., Pearson, J., Geddes, J., & O’brien, G. (2002). A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology, 16(1), 93–101.
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A. & Perrin, J. M. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(Supplement 2), S69–76.
Egan, A. M., Dreyer, M. L., Odar, C. C., Beckwith, M., & Garrison, C. B. (2013). Obesity in young children with autism spectrum disorders: Prevalence and associated factors. Childhood Obesity, 9, 125–31.
Findling, R. L., Horwitz, S. M., Birmaher, B., Kowatch, R. A., Fristad, M. A., Youngstrom, E. A., ... & Arnold, L. E. (2011). Clinical characteristics of children receiving antipsychotic medication. Journal of Child and Adolescent Psychopharmacology, 21(4), 311–19.
Frazier, T. W., Shattuck, P. T., Narendorf, S. C., Cooper, B. P., Wagner, M., & Spitznagel, E. L. (2011). Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(6), 571–79.
Frazier, T. W., Youngstrom, E. A., Haycook, T., Sinoff, A., Dimitriou, F., Knapp, J., & Sinclair, L. (2010). Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 20(3), 167–77.
Gleason, M. M., Egger, H. L., Emslie, G. J., Greenhill, L. L., Kowatch, R. A., Lieberman, A. F., ... & Zeanah, C. H. (2007). Psychopharmacological treatment for very young children: Contexts and guidelines. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 1532–72.
Hassiotis, A., Robotham, D., Canagasabey, A., Romeo, R., Langridge, D., Blizard, R., Murad, S., & King, M. (2009). Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities. The American Journal of Psychiatry, 166, 1278–85.
Hilt, R. J., Chaudhari, M., Bell, J. F., Wolf, C., Koprowicz, K., & King, B. H. (2014). Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. Journal of Child and Adolescent Psychopharmacology, 24(2), 83–9.
Jensen, P. S., Hinshaw, S. P., Swanson, J. M., Greenhill, L. L., Conners, C. K., Arnold, L. E., ... & March, J. S. (2001). Findings from the NIMH multimodal treatment study of ADHD (MTA): Implications and applications for primary care providers. Journal of Developmental & Behavioral Pediatrics, 22(1), 60–73.
Kaplan, G., & McCracken, J. T. (2012). Psychopharmacology of autism spectrum disorders. Pediatric Clinics of North America, 59(1), 175–87.
Lòpez-De Fede, A., Vyavaharkar, M., & Bellinger, J. D. (2014). Antipsychotic prescriptions for children aged 5 years or younger. SAGE Open, 4(4), 2158244014555116.
Maayan, L., & Correll, C. U. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21(6), 517–35.
Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121, 441–48.
Martínez-Ortega, J. M., Funes-Godoy, S., Díaz-Atienza, F., Gutiérrez-Rojas, L., Pérez-Costillas, L., & Gurpegui, M. (2013). Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. European Child & Adolescent Psychiatry, 22(8), 457–79.
Medicaid Medical Directors Learning Network. (2010). Antipsychotic medication use in medicaid children and adolescents: Report and resource guide from a 16-state study. Medicaid medical directors learning network and rutgers center for education and research on mental health therapeutics. Retrieved from: http://rci.rutgers.edu/~cseap/ MMDLNAPKIDS.html.
Myers, S. M. (2007). The status of pharmacotherapy for autism spectrum disorders. Expert Opinion on Pharmacotherapy, 8, 1579–603.
Myers, S. M., & Plauche Johnson, C. (2007). Management of children with autism spectrum disorders. Pediatrics, 120, 1162–82.
National Institute for Health and Care Excellence. (2014). NICE quality standard 51. guidance.nice.org.uk/qs51.
Owens, J. A., Spirito, A., & McGuinn, M. (2000). The Children’s sleep habits questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep, 23(8), 1043–51.
Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., ... & Correll, C. U. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child & Adolescent Psychiatry, 55(6), 456–68.
Peters, B., Williams, K. C., Gorrindo, P., Rosenberg, D., Lee, E. B., Levitt, P., & Veenstra-VanderWeele, J. (2014). Rigid–compulsive behaviors are associated with mixed bowel symptoms in autism spectrum disorder. Journal of Autism and Developmental Disorders, 44(6), 1425–32.
Posey, D. J., & McDougle, J. (2000). The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review of Psychiatry, 8, 45–63.
Rosenberg, R. E., Mandell, D. S., Farmer, J. E., Law, J. K., Marvin, A. R., & Law, P. A. (2010). Psychotropic medication use among children with autism spectrum disorders enrolled in a National Registry, 2007–2008. Journal of Autism and Developmental Disorders, 40, 342–51.
Spencer, D., Marshall, J., Post, B., Kulakodlu, M., Newschaffer, C., Dennen, T., Azocar, F., & Jain, A. (2013). Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics, 132(5), 833–40.
Vitiello, B., Correll, C., van Zwieten-Boot, B., Zuddas, A., Parellada, M., & Arango, C. (2009). Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology, 19(9), 629–35.
Volkmar, Fred, et al. (2014). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 53(2), 237–57.
Yen, J., Grover, M., & Mao, A. (2011). Antipsychotics and autism: Weight, metabolism, and safety. Child and Adolescent Psychopharmacology News, 16(1), 1–11.
Zuckerman, K. E., Hill, A. P., Guion, K., Voltolina, L., & Fombonne, E. (2014). Overweight and obesity: Prevalence and correlates in a large clinical sample of children with autism spectrum disorder. Journal of Autism and Developmental Disorders, 44, 1708–19.
JL conceptualized study design and data analyses, drafted the initial manuscript, and approved the final manuscript as submitted; DD, YL, and JV conceptualized study design and data analyses, critically reviewed the manuscript, and approved the final manuscript as submitted; AS carried out all data analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted; EA conceptualized study design and data analyses, coordinated and supervised data collection at two of the sites, critically reviewed the manuscript, and approved the final manuscript as submitted.
This research was supported by a grant given to the Autism Treatment Network, Autism Intervention Research Network on Physical Health by the Health Resources Services Administration (HRSA Grant# UA3MC11054). This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the US Government. This work was conducted through the Autism Speaks Autism Treatment Network serving as the Autism Intervention Research Network on Physical Health. We would also like to thank the families, their children, and all of the research staff involved in this project.
Conflict of interest
Dr. Veenstra-VanderWeele has consulted with Roche Pharmaceuticals, Novartis, and SynapDx and has had research funding from Roche Pharmaceuticals, Novartis, SynapDx, Seaside Therapeutics, Forest, and Sunovion. He receives an honorarium for editorial work from Springer and John Wiley and Sons. Dr. Anagnostou consultation fees and advisory boards include Roche; Industry funding: SynapDx, Sanofi-Aventis; Other funding sources include: Canadian Institutes of Health Research, Ontario Brain Institute, DOD, Autism Speaks, National Centers of Excellence, Physician Services Incorporated; Royalties received by: APPI and Springer. The remaining authors declare that they have no conflict of interest.
About this article
Cite this article
Lake, J.K., Denton, D., Lunsky, Y. et al. Medical Conditions and Demographic, Service and Clinical Factors Associated with Atypical Antipsychotic Medication Use Among Children with An Autism Spectrum Disorder. J Autism Dev Disord 47, 1391–1402 (2017). https://doi.org/10.1007/s10803-017-3058-8
- Autism spectrum disorder
- Atypical antipsychotic medication